HomePulnovo Medical

Pulnovo Medical

Pulnovo Medical Completes the world’s 1st Pulmonary Hypertension RX Device RCT Study After Achieving FDA Breakthrough Designation

The clinical data showed that: percutaneous pulmonary artery denervation significantly improved the 6-minute step of polytype pulmonary hypertension, and the mean pulmonary artery pressure and pulmonary vascular resistance were significantly reduced without related complications. In addition, percutaneous pulmonary artery denervation also has a therapeutic effect on mixed pre- and post-capillary pulmonary hypertension secondary to left heart failure.